IN VIVO is a prestigious academic journal published by the International Institute of Anticancer Research, dedicated to advancing the fields of biochemistry, genetics, molecular biology, cancer research, and pharmacology. With its ISSN 0258-851X and E-ISSN 1791-7549, this journal has been a key contributor to innovative research since its inception in 1987, providing a crucial platform for the dissemination of significant findings in its scope. With an impressive impact reflected in its quartile rankings (Q2 in Biochemistry, Genetics and Molecular Biology and Medicine; Q3 in Cancer Research and Pharmacology), IN VIVO reaches a global audience comprising researchers, health professionals, and students. Although it operates on a subscription basis, the journal’s commitment to scientific excellence and rigorous peer review ensures that all published works maintain high quality and relevance. Notably positioned in Scopus ranks within the 36th to 59th percentiles across various categories, IN VIVO continues to be a vital resource for cutting-edge research and developments, solidifying its importance within the scientific community.

AUTOIMMUNITY, published by Taylor & Francis Ltd, is an influential journal dedicated to advancing the understanding of autoimmune diseases through rigorous research and scholarly discourse. With an ISSN of 0891-6934 and an E-ISSN of 1607-842X, this journal serves as a key resource for immunologists, medical professionals, and students engaged in investigating the complex mechanisms underpinning autoimmunity. Operating from the United Kingdom, it offers valuable insights into immunological and allergic phenomena, achieving respectable Scopus rankings in both Immunology and Allergy (106/233, Q3) and Immunology and Microbiology (125/236, Q2). Covering a broad spectrum of topics since its inception in 1988, AUTOIMMUNITY encourages the dissemination of innovative research findings and aims to enhance collaborative efforts within the field. While it currently adopts a conventional access model, the journal's commitment to quality and excellence positions it as a vital platform for those looking to engage with cutting-edge research in immunology.

APMIS is a distinguished academic journal published by WILEY that serves as a vital resource for researchers and practitioners in the fields of Immunology, Allergy, Microbiology, and Pathology. Established in 1988 and continuing its mission through 2024, this journal facilitates the dissemination of high-quality research findings, contributing to the intersection of multiple disciplines within the medical sciences. With an ISSN of 0903-4641 and an E-ISSN of 1600-0463, APMIS is categorized in 2023's Q2 and Q3 quartiles across various domains, reflecting its significant impact, with rankings such as #50/208 in Pathology and Forensic Medicine and #121/233 in Immunology and Allergy. Although it currently does not offer open access options, the journal’s rigorous peer-review process ensures that published articles maintain the highest standards of scholarship. With its focus on innovative research, APMIS continues to occupy a pivotal role for those seeking to advance their expertise and contribute to scientific dialogue in these essential fields.

IMMUOLOGY LETTERS, published by Elsevier, is a distinguished journal in the field of immunology, focusing on the latest advancements and findings that significantly influence immunological research and clinical applications. Established in 1979, the journal has evolved to cater to a global readership, featuring high-quality peer-reviewed articles across a diverse spectrum of topics related to immunity and allergic responses. With an impressive Q2 category ranking in both Immunology and Allergy as of 2023, it holds a strong position within the scientific community, evidenced by its commendable Scopus rankings (Rank #71/233 in Medicine - Immunology and Allergy and Rank #85/236 in Immunology and Microbiology - Immunology). While primarily subscription-based, the journal aims to foster knowledge dissemination that encourages collaboration among researchers and practitioners alike, making significant contributions to the understanding of immune mechanisms. The journal is integral for educators, students, and professionals aiming to stay abreast of current trends and breakthroughs in the immune system's intricate functions.

ImmunoTargets and Therapy is a leading open access journal published by DOVE MEDICAL PRESS LTD, dedicated to advancing the field of immunology and its various therapeutic applications. Since its inception in 2012, the journal has rapidly become a vital resource for researchers, professionals, and students, achieving notable recognition with a Q1 ranking in both Immunology and Immunology and Allergy categories as of 2023. With an impressive Scopus ranking of #22 out of 233 in Medicine - Immunology and Allergy, and #25 out of 236 in Immunology and Microbiology, this journal maintains a 90th percentile standing in its field. ImmunoTargets and Therapy not only publishes original research articles, reviews, and clinical studies, but also fosters an inclusive platform for the dissemination of innovative findings critical to the fight against immunological disorders. Based in New Zealand, it serves a global audience, promoting knowledge exchange and collaboration through its open access model.

The Annual Review of Immunology, published by Annual Reviews, is a premier journal that has been contributing to the field of immunology since its establishment in 1983. With a strong reputation highlighted by its impressive impact factor and top-tier rankings—holding the Q1 category in both Immunology and Immunology and Allergy, alongside significant Scopus Rankings—this journal serves as an essential resource for researchers, professionals, and students alike. The Annual Review of Immunology covers the latest advancements and critical developments in the domain, fostering a better understanding of immune responses and disorders. Although it is not an open-access journal, it provides comprehensive reviews that synthesize emerging data and trends, making it indispensable for those at the forefront of immunological research. With volumes anticipated through 2024, it continues to set the standard for high-quality scholarly publications in the field.

AUTOIMMUNITY REVIEWS is an esteemed journal in the field of immunology and allergy, published by Elsevier and located in the Netherlands. With a remarkable impact reflected in its Q1 category rankings for both Immunology and Allergy, this journal stands at the forefront of advancing research and knowledge in autoimmune diseases. Its Scopus rankings are particularly notable, placing it at #14 in the Immunology and Allergy category and #17 in the broader scope of Immunology and Microbiology, underscoring its influential role in the scientific community with a commendable 94th percentiles in both domains. Since its inception in 2002, AUTOIMMUNITY REVIEWS has provided a multidisciplinary platform for researchers and practitioners to share landmark studies, case reports, and reviews that propel the understanding of autoimmune disorders. Although it does not currently operate under an open-access model, the journal ensures rigorous peer review and high-quality publications, making it an essential resource for anyone looking to stay informed about the latest developments in autoimmune research.

Immunotherapy Advances, published by Oxford University Press, stands at the forefront of the rapidly evolving field of immunology and microbe interactions, focusing specifically on novel immunotherapeutic strategies and their clinical applications. Established in 2021, this peer-reviewed journal aims to disseminate high-quality research that contributes to the understanding and advancement of immunotherapeutic techniques, potentially transforming patient care in immunology. With a current Scopus rank of #140 out of 236 in the realm of Immunology, placing it in the 40th percentile, Immunotherapy Advances is positioned to be an integral resource for researchers, healthcare professionals, and students eager to stay updated with groundbreaking findings and methodologies. The journal is dedicated to fostering innovative discussions and collaborations, ensuring open access to vital research that influences treatment paradigms globally.

CURRENT OPINION IN NEUROLOGY is a premier academic journal dedicated to providing insightful overviews and critical analyses across all areas of neurology and clinical neurology. Published by Lippincott Williams & Wilkins, this esteemed journal boasts an impressive impact factor, highlighting its influence and relevance in the field—positioning it in the Q1 category for both neurology and clinical neurology as of 2023. With its comprehensive coverage, the journal serves as a vital resource for researchers, healthcare professionals, and students aiming to stay abreast of the latest developments, trends, and breakthroughs in neurological science and practice. Though not open access, articles are available via institutional subscriptions or individual purchase, ensuring that vital research remains accessible to a wide audience. Covering research from its inception in 1993 to ongoing studies in 2024, CURRENT OPINION IN NEUROLOGY stands out as an essential platform for disseminating knowledge and fostering dialogue within the dynamic and evolving landscape of neurology.

HUMAN IMMUNOLOGY, published by Elsevier Science Inc, serves as a critical platform for disseminating research in the fields of immunology and allergy, as well as various aspects of miscellaneous medicine since its inception in 1980. With an ISSN of 0198-8859 and E-ISSN 1879-1166, this journal is pivotal for researchers and practitioners looking to advance their understanding of human immune responses and related conditions. The journal currently holds a respectable position within its field, as highlighted by its 2023 Scopus ranks—#114/233 in Immunology and Allergy and #132/236 in Immunology and Microbiology. Moreover, it maintains a Q2 quartile ranking in both Immunology and Allergy and miscellaneous Medicine, underscoring its influence and reach within the scientific community. Although it does not currently offer Open Access options, HUMAN IMMUNOLOGY remains dedicated to providing valuable insights and fostering academic discourse within its discipline, characterized by a rigorous peer-review process and a focus on innovative research trajectories.